OncoMatch/Clinical Trials/NCT06415708

Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

Is NCT06415708 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Obinutuzumab Combined With Bendamustine for b cell lymphoma.

Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06415708Data as of May 2026

Treatment: Obinutuzumab Combined With Bendamustine — This is a prospective, single-center, single-arm clinical study to evaluate the efficacy and safety of maintenance therapy with obinutuzumab for 2 years in patients ≥ 18 years of age with newly diagnosed mature B-cell lymphoma (including follicular lymphoma\[FL\], marginal zone cell lymphoma\[MZL\] , waldenström macroglobulinemia\[WM\], hairy-cell leukemia variant\[HCL-v\]) who achieved ≥ PR after 6 cycles of obinutuzumab in combination with bendamustine.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Biomarker criteria

Required: CD20 positivity

histological documentation of CD20 positivity

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: chemotherapy

Mature B-cell lymphoma previously treated with chemotherapy, immunotherapy, or radiation therapy

Cannot have received: immunotherapy

Mature B-cell lymphoma previously treated with chemotherapy, immunotherapy, or radiation therapy

Cannot have received: radiation therapy

Mature B-cell lymphoma previously treated with chemotherapy, immunotherapy, or radiation therapy

Lab requirements

Blood counts

hemoglobin ≥ 7 g/dL; absolute neutrophil count ≥ 1.0 × 10^9/L; platelet count ≥ 50 × 10^9/L

Kidney function

creatinine clearance ≥ 30 mL/min

Liver function

AST or ALT ≤ 2.5 x ULN; Serum bilirubin ≤ 2 x ULN (≤ 3 x ULN for patients with Gilbert's syndrome)

Adequate blood function ... hemoglobin ≥ 7 g/dL absolute neutrophil count ≥ 1.0 × 10^9/L platelet count ≥ 50 × 10^9/L; Normal laboratory values: creatinine clearance ≥ 30 mL/min AST or ALT ≤ 2.5 x ULN Serum bilirubin ≤ 2 x ULN (≤ 3 x ULN for patients with Gilbert's syndrome)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify